ストックスクリーナーアプリを入手
10.67
0.56%
-0.06
アフターアワーズ：
10.78
0.11
+1.03%
Intellia Therapeutics Inc (NTLA) 最新ニュース
Intellia Therapeutics Inc (NTLA) Cash Flow - TradingKey
NTLA|Intellia Therapeutics Inc|Price:10.730|Chg%:-0.370 - TradingKey
Intellia Therapeutics CFO sells $91,248 in stock By Investing.com - Investing.com UK
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia Therapeutics CFO sells $91,248 in stock - Investing.com
Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade - Stock Titan
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
NTLA|Intellia Therapeutics Inc|Price:10.680|Chg%:-0.050 - TradingKey
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
Intellia Therapeutics Stock Short Interest Falls to 44.41% - Quiver Quantitative
Intellia Stock And 2 Growth Shares With Clear Earnings Upside - simplywall.st
(NTLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Intellia Therapeutics (NTLA) Income Statement & Earnings - Moomoo
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NTLA) Dips 4% as Gene Editing Stock Faces Support Test Near $10.81Put Dominated - dars.gov.et
Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing? - Sahm
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
NTLA Downgraded by Wolfe Research -- Rating Changed to Underperf - GuruFocus
Intellia Therapeutics stock trades below recent highs as gene-editing pipeline progresses after late - ad-hoc-news.de
NTLA Downgraded by Wolfe Research -- Rating Changed to Underperform - GuruFocus
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
Intellia stock downgraded by Wolfe Research on valuation concerns - Investing.com
Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential (NTLA) - Seeking Alpha
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch PlansWhat's Changed - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics (NTLA) Could Be 37% Below Fair Value On Gene Editing Hopes - Sahm
NTLA Maintained by Wedbush -- Price Target Raised to $17.00 - GuruFocus
Intellia Therapeutics (NTLA) BofA Securities 2025 Healthcare Conference Summary - Quartr
NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jul 2026 $NTLA - MarketBeat
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success - Yahoo Finance
Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating - Moomoo
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance
NTLA Stock Price Prediction 2025-2026 | Intellia Therapeutics Inc Forecast - 24/7 Wall St.
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):